The role of SET/I2PP2A in canine mammary tumors
暂无分享,去创建一个
T. Nakagawa | T. Usui | Yuiko Tanaka | Hao-Ping Liu | Shih-Chieh Chang | T. Ohama | Koichi Sato | Ryotaro Yabe | Shunya Tsuji | Satoru Kake | Shuhei Enjoji | Sayaka Hanasaki | H. Hayase
[1] J. Xing,et al. Paclitaxel resistance in MCF-7/PTX cells is reversed by paeonol through suppression of the SET/phosphatidylinositol 3-kinase/Akt pathway. , 2015, Molecular medicine reports.
[2] M. Vitek,et al. The therapeutic effects of SET/I2PP2A inhibitors on canine melanoma , 2015, The Journal of veterinary medical science.
[3] M. Cristofanilli,et al. Molecular characterization and targeted therapeutic approaches in breast cancer , 2015, Breast Cancer Research.
[4] J. Sur,et al. Effects of Obesity and Obesity-Related Molecules on Canine Mammary Gland Tumors , 2015, Veterinary pathology.
[5] Hongsheng Wang,et al. Overexpression of PP2A inhibitor SET oncoprotein is associated with tumor progression and poor prognosis in human non-small cell lung cancer , 2015, Oncotarget.
[6] George A. Calin,et al. From the Biology of PP2A to the PADs for Therapy of Hematologic Malignancies , 2015, Front. Oncol..
[7] F. Rojo,et al. PP2A inhibition determines poor outcome and doxorubicin resistance in early breast cancer and its activation shows promising therapeutic effects , 2015, Oncotarget.
[8] Hao Liu,et al. SET-mediated NDRG1 inhibition is involved in acquisition of epithelial-to-mesenchymal transition phenotype and cisplatin resistance in human lung cancer cell. , 2014, Cellular signalling.
[9] F. Rojo,et al. Deregulation of the PP2A Inhibitor SET Shows Promising Therapeutic Implications and Determines Poor Clinical Outcome in Patients with Metastatic Colorectal Cancer , 2014, Clinical Cancer Research.
[10] L. Cai,et al. NF-κB Affects Proliferation and Invasiveness of Breast Cancer Cells by Regulating CD44 Expression , 2014, PloS one.
[11] H. Zhang,et al. Nestin positively regulates the Wnt/β-catenin pathway and the proliferation, survival and invasiveness of breast cancer stem cells , 2014, Breast Cancer Research.
[12] Colin J. Daniel,et al. Targeting c-MYC by antagonizing PP2A inhibitors in breast cancer , 2014, Proceedings of the National Academy of Sciences.
[13] T. Mizuno,et al. Characterization of SET/I2PP2A Isoforms in Dogs , 2014, The Journal of veterinary medical science.
[14] M. Caligiuri,et al. PP2A-activating drugs selectively eradicate TKI-resistant chronic myeloid leukemic stem cells. , 2013, The Journal of clinical investigation.
[15] T. Uchide,et al. L-type amino acid transporter 1 (LAT1): a new therapeutic target for canine mammary gland tumour. , 2013, Veterinary journal.
[16] G. Stark,et al. PHF20 regulates NF-κB signalling by disrupting recruitment of PP2A to p65 , 2013, Nature Communications.
[17] D. Perrotti,et al. Protein phosphatase 2A: a target for anticancer therapy. , 2013, The Lancet. Oncology.
[18] L. Pannell,et al. DNAJB6 chaperones PP2A mediated dephosphorylation of GSK3β to downregulate β-catenin transcription target, osteopontin , 2012, Oncogene.
[19] Kuen-Feng Chen,et al. CIP2A is a target of bortezomib in human triple negative breast cancer cells , 2012, Breast Cancer Research.
[20] F. Gärtner,et al. Canine tumors: a spontaneous animal model of human carcinogenesis. , 2012, Translational research : the journal of laboratory and clinical medicine.
[21] C. Van Ginneken,et al. Canine mammary tumours, an overview. , 2011, Reproduction in domestic animals = Zuchthygiene.
[22] M. Vitek,et al. SET oncoprotein overexpression in B-cell chronic lymphocytic leukemia and non-Hodgkin lymphoma: a predictor of aggressive disease and a new treatment target. , 2011, Blood.
[23] V. Zappulli,et al. Development, Anatomy, Histology, Lymphatic Drainage, Clinical Features, and Cell Differentiation Markers of Canine Mammary Gland Neoplasms , 2011, Veterinary pathology.
[24] A. Teleman,et al. PP2A regulatory subunit PP2A-B' counteracts S6K phosphorylation. , 2010, Cell metabolism.
[25] D. Brautigan,et al. Endotoxin Conditioning Induces VCP/p97-mediated and Inducible Nitric-oxide Synthase-dependent Tyr284 Nitration in Protein Phosphatase 2A* , 2010, The Journal of Biological Chemistry.
[26] E. Colado,et al. The synergy of panobinostat plus doxorubicin in acute myeloid leukemia suggests a role for HDAC inhibitors in the control of DNA repair , 2009, Leukemia.
[27] M. Mochizuki,et al. Establishment of four pairs of canine mammary tumour cell lines derived from primary and metastatic origin and their E-cadherin expression. , 2006, Veterinary and comparative oncology.
[28] F. Queiroga,et al. Role of steroid hormones and prolactin in canine mammary cancer , 2005, The Journal of Steroid Biochemistry and Molecular Biology.
[29] V. Janssens,et al. Protein phosphatase 2A: a highly regulated family of serine/threonine phosphatases implicated in cell growth and signalling. , 2001, The Biochemical journal.
[30] P. McNamara,et al. Regulation of Histone Acetylation and Transcription by INHAT, a Human Cellular Complex Containing the Set Oncoprotein , 2001, Cell.
[31] N. Shikama,et al. Functional Interaction between Nucleosome Assembly Proteins and p300/CREB-Binding Protein Family Coactivators , 2000, Molecular and Cellular Biology.
[32] K. Nagata,et al. Functional domains of template-activating factor-I as a protein phosphatase 2A inhibitor. , 1999, Biochemical and biophysical research communications.
[33] S. Schreiber,et al. Protein phosphatase 2A interacts with the 70-kDa S6 kinase and is activated by inhibition of FKBP12-rapamycinassociated protein. , 1999, Proceedings of the National Academy of Sciences of the United States of America.
[34] J. Chen,et al. Regulation of protein serine-threonine phosphatase type-2A by tyrosine phosphorylation. , 1992, Science.
[35] Marieke,et al. Can, a putative oncogene associated with myeloid leukemogenesis, may be activated by fusion of its 3' half to different genes: characterization of the set gene , 1992, Molecular and cellular biology.
[36] M. Vitek,et al. A potential therapeutic application of SET/I2PP2A inhibitor OP449 for canine T-cell lymphoma. , 2013, The Journal of veterinary medical science.